ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.70
+3.70%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-11.8%
Return on equity
-11.6%
Return on assets
-13.9%
Return on invested capital
0.00x
Asset turnover
-$66.9M
Cash from operations
$12
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026